GlassScriptPhysician profile
Margie A Cook
NPI 1013153857
$8,176.89
in general payments reported to CMS, 2019-2025
26 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,776 · 2023: $2,115 · 2024: $1,810 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,033 · Education: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,033.12 |
| Education | $468.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,334.45 | 2021-2025 | |
| Abbvie INC. | $1,025.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $821.92 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $810.49 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $778.76 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $728.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $580.49 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $467.89 | 2021-2025 | |
| Ucb, INC. | $331.31 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $191.88 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $169.93 | 2021-2025 | Aklief, Epsolay, Oracea |
| Incyte Corporation | $131.94 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.29 | 2024-2025 | Siliq, Targretin, Duobrii |
| Almirall LLC | $113.26 | 2022-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $108.06 | 2023-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $105.95 | 2024 | |
| Amgen INC. | $93.11 | 2023-2024 | Otezla |
| Mayne Pharma Commercial LLC | $91.02 | 2022-2023 | |
| Dermavant Sciences, INC. | $39.34 | 2023-2024 | Vtama |
| Mallinckrodt Hospital Products INC. | $28.12 | 2024 | Acthar |
| Pfizer INC. | $23.68 | 2023 | |
| Dermira, INC. | $21.28 | 2021 | |
| Organon LLC | $17.20 | 2025 | |
| Epi Health, LLC | $17.17 | 2022 | |
| Botanix Sb INC | $16.99 | 2025 | Sofdra |
| Genentech USA, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margie Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.